Literature DB >> 18827057

Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome.

J H Rand1, X X Wu, A S Quinn, D J Taatjes.   

Abstract

The phospholipid binding protein, annexin A5 (AnxA5), has potent anticoagulant properties that result from its forming 2-dimensional crystals over phospholipids, blocking the availability of the phospholipids for critical coagulation enzyme reactions. This article reviews the evidence that antiphospholipid antibodies can disrupt this anticoagulant shield and unmask thrombogenic anionic phospholipids, which may thereby contribute to thrombosis in patients with the antiphospholipid syndrome (APS). This mechanism for thrombosis in APS can be monitored with coagulation assays for resistance to anticoagulant activity of AnxA5.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827057     DOI: 10.1177/0961203308095029

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  18 in total

Review 1.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

2.  Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Authors:  D M Wahezi; N T Ilowite; X X Wu; L Pelkmans; B Laat; L E Schanberg; J H Rand
Journal:  Lupus       Date:  2013-05-20       Impact factor: 2.911

Review 3.  Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Annexin-A5 resistance and non-criteria antibodies for the diagnosis of seronegative antiphospholipid syndrome.

Authors:  Virginie Planche; Arsene Mékinian; Théo Ghelfenstein Ferreira; François Delhommeau; Catherine Johanet; Grigorios Gerotziafas; Marie Bornes; Jonathan Cohen; Gilles Kayem; Olivier Fain
Journal:  Clin Rheumatol       Date:  2020-01-10       Impact factor: 2.980

5.  Prediction of Antiphospholipid syndrome using Annexin A5 competition assay in patients with SLE.

Authors:  Avital Avriel; Stela Fleischer; Michael Friger; Ora Shovman; Gal Neuman; Yehuda Shoenfeld; Mahmoud Abu-Shakra
Journal:  Clin Rheumatol       Date:  2016-10-04       Impact factor: 2.980

6.  Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus.

Authors:  Antoni Hrycek; Paweł Cieślik
Journal:  Rheumatol Int       Date:  2011-02-05       Impact factor: 2.631

Review 7.  Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy.

Authors:  Anthony S Quinn; Xiao-Xuan Wu; Jacob H Rand; Douglas J Taatjes
Journal:  Micron       Date:  2012-03-23       Impact factor: 2.251

8.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

9.  Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome.

Authors:  Daniel Navarro-Carpentieri; Maria Del Carmen Castillo-Hernandez; Karim Majluf-Cruz; Guillermo Espejo-Godinez; Paola Carmona-Olvera; Manuel Moreno-Hernandez; Yolanda Lugo-García; Jesús Hernandez-Juarez; Luis Loarca-Piña; Irma Isordia-Salas; Abraham Majluf-Cruz
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

10.  The role of hydroxychloroquine in catastrophic antiphospholipid syndrome case: Series of two case reports and review of literature.

Authors:  Zakaria Hindi; Mosa Hussein; Abdallah Gad; Abdallah A Khaled; Talal Zahoor
Journal:  SAGE Open Med Case Rep       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.